BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers
Status:
Withdrawn
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II open label fixed dose study in subjects with advanced, metastatic, or
refractory endometrial or ovarian, fallopian tube, or primary peritoneal cancer with PI3
kinase pathway activation as demonstrated by PIK3CA gene mutation, PTEN gene mutation, or
PTEN null/low protein expression.